- Previous Close
1.4100 - Open
1.3800 - Bid 1.3850 x --
- Ask 1.3900 x --
- Day's Range
1.3650 - 1.4100 - 52 Week Range
1.0800 - 1.8600 - Volume
1,263,050 - Avg. Volume
1,808,814 - Market Cap (intraday)
1.006B - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9600 - Earnings Date Feb 20, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 7, 2022
- 1y Target Est
1.35
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics, QML Pathology, TML Pathology, Abbott Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories, medical centers, patient collection centers, and community imaging centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.
www.healius.com.au4,329
Full Time Employees
June 30
Fiscal Year Ends
Sector
Industry
Recent News: HLS.AX
View MorePerformance Overview: HLS.AX
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HLS.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HLS.AX
View MoreValuation Measures
Market Cap
1.01B
Enterprise Value
2.29B
Trailing P/E
--
Forward P/E
125.00
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.52
Price/Book (mrq)
0.98
Enterprise Value/Revenue
1.31
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-1.27%
Return on Assets (ttm)
1.34%
Return on Equity (ttm)
-3.08%
Revenue (ttm)
1.79B
Net Income Avi to Common (ttm)
-32M
Diluted EPS (ttm)
-0.9600
Balance Sheet and Cash Flow
Total Cash (mrq)
115.4M
Total Debt/Equity (mrq)
136.23%
Levered Free Cash Flow (ttm)
-195.19M